S Serum Analysis Centre Private Limited - Due diligence report

A 360° intelligence report on Serum Analysis: trust score, financial health, credit view, compliance, directors, growth and distress signals…

2002-09-17 Kolkata, West Bengal Active Unlisted Active Compliant
Share
SS S Serum Analysis Centre Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Serum Analysis — 360° Intelligence Report

Generated from MCA filings & public records
92/100
Trust Score
Low Risk

Serum Analysis is assessed as Low Risk with a Trust Score of 92/100. Serum Analysis is an active private limited indian non-government company incorporated in 2002, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. S Serum Analysis Centre Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
92/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
93/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
70/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 70/100 Moderate
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 2 open (50.00 Lakh) · 2 satisfied (5.14 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Axis Bank Limited1 48.0 cr
Others2 48.0 cr
United Bank Of India1 48.0 cr
Compliance Score: 93/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 1 court forum(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
KALIDAS CHAKRABARTI 01234567 Director 01/04/2018 6 yrs Approved
SANJIB ACHARYA 01234567 Director 01/04/2018 6 yrs Approved
NIVEDITA ACHARYA 01234567 Director 01/04/2018 6 yrs Approved
GAYATRI ACHARYA 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2022)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2022 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
1
Group entities
1
Capital events
2 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Serum Edumotive Private Limited Subsidiary Company 74.00%

Key managerial personnel: SANJIB ACHARYA (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 95 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +38% over 4 year(s).
Latest year revenue grew 1.42.
Profit expanded 2.1x year-on-year.
Asset base grew 24% - capacity expansion.
Operating for 23+ years.
Active EPFO - real payroll on record.
Distress signals & risk flags
2 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence92/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment82/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 2 open charge(s) of 50.00 Lakh already registered.
  • Compliance record supports lending.
Investor view92/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 4 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
08 Jul 2025
Charge satisfied
Axis Bank Limited
31 Mar 2025
Latest balance sheet
Filed with ROC
22 Jan 2025
Charge created
Axis Bank Limited - 5.00 cr
24 Jul 2024
Charge created
Others - 25.00 Lakh
21 Sep 2023
Charge created
Others - 25.00 Lakh
30 Nov 2021
Director ceased
GAYATRI ACHARYA
24 Aug 2018
Securities allotted
150000 Equity Shares - 45.00 Lakh raised
24 Feb 2018
Director appointed
GAYATRI ACHARYA (Director)
24 Jun 2013
Securities allotted
300000.00 Equity Shares - 30.00 Lakh raised
28 Dec 2007
Charge satisfied
United Bank Of India
02 Sep 2004
Director appointed
KALIDAS CHAKRABARTI (Director)
26 Dec 2003
Charge created
United Bank Of India - 13.52 Lakh
17 Sep 2002
Incorporated
Registered with Roc Kolkata
Director appointed
SANJIB ACHARYA (Managing Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
4 active director(s) / partner(s); board looks stable and experienced.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2022 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Genepath Dx U74999PN2019PTC181759 Pune, Maharashtra, India
Dr. Khannas Pathcare Private Limited U51100DL2004PTC126416 New Delhi, Delhi, India
Dr Lal Pathlabs U74220MP2019PTC049171 Indore, Madhya Pradesh, India
South-Gujarat Cardiac Care Private Limited U85110GJ2013PTC073815 Surat, Gujarat, India
Nueclear U74120MH2011PLC212839 Navi Mumbai, Maharashtra, India
Centuryhospital U85110TG2012PTC080025 Hyderabad, Telangana, India
Gangadeep Medicare Services Private Limited U85110DL1998PTC092966 New Delhi, Delhi, India
North Star Diagnostics Private Limited U33125GJ2021PTC119876 Ahmedabad, Gujarat, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Serum Analysis before audits and certifications: compliance score 93/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Serum Analysis: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 70/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Serum Analysis - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 92/100, distress signals and MSME payment-delay disclosures - know whether Serum Analysis pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Serum Analysis - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Serum Analysis an active company?

Serum Analysis has MCA status “Active” with a compliance score of 93/100 (Low Risk).

Is Serum Analysis financially healthy?

Serum Analysis has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.

Should I do business with Serum Analysis?

Its overall Trust Score is 92/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Serum Analysis?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 4 active director(s) are on record.

Does Serum Analysis have loans or charges against its assets?

2 open charge(s) are registered against its assets, and 2 earlier charge(s) stand satisfied.

Is Serum Analysis up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 93/100 (Low Risk).

Is it risky to lend to Serum Analysis?

Its Credit Risk Score is 70/100 (Moderate). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.